US FDA clears HELP Therapeutics’ IND application for universal iPSC-derived HiCM-188 cell therapy to treat end-stage heart failure: Nanjing, China Wednesday, October 23, 2024, 1 ...

Samsung Biologics inks largest manufacturing deal with Asia-based pharma company: Incheon, S. Korea Wednesday, October 23, 2024, 09:00 Hrs [IST] Samsung Biologics, a global contra ...

Anticipating notification, TN IPGA starts training programme for drug inspector and medical devices officer exams: Peethaambaran Kunnathoor, Chennai Wednesday, October 23, 2024, 0 ...

India and Germany to advance translational research in neurosciences with focus on pain management: Nandita Vijayasimha, Bengaluru Wednesday, October 23, 2024, 08:00 Hrs [IST] Ind ...

DTAB recommends amendment of Rule 64 related to qualification of competent person for wholesale license: Gireesh Babu, New Delhi Wednesday, October 23, 2024, 08:00 Hrs [IST] The D ...

The Pharmacy Council of India (PCI) has informed all State Pharmacy Councils that the council has initiated continuing education programmes and skill development programmes to improve the skill sets ...

Modern HR technology reshaping workforce management for healthcare providers: Srinivas Bhararthy: Shardul Nautiyal, Mumbai Wednesday, October 23, 2024, 08:00 Hrs [IST] The healthc ...

Justice D.Y. Chandrachud has stressed on intersection of law, ethics and medical innovation in gene therapy for treatment of rare diseases. Speaking after inaugurating a conference on ‘Gene Therapy ...

In the dynamic pharmaceutical world, the practice of launch forecasting and market research has always been a complex blend of art and science. According to the Oxford dictionary, “forecasting” is a ...

Angelini Pharma, Cureverse enter exclusive global option agreement to develop & commercialize innovative brain health asset, CV-01: Rome, Italy Tuesday, October 22, 2024, 17:00 Hr ...

Global pharma major Lupin Limited (Lupin) announced the appointment of Claus Jepsen as president, global specialty. He brings ...

Foresee Pharma announces preliminary results from phase 1 trial, highlighting promising safety, tolerability and PK profile of linvemastat: Taipei, Taiwan Tuesday, October 22, 202 ...